Why the study?
Does bezafibrate improve severe hyperlipidemia in a patient with an LPL gene mutation who is resistant to fenofibrate and atorvastatin?
Does bezafibrate improve severe hyperlipidemia in a patient with an LPL gene mutation who is resistant to fenofibrate and atorvastatin?
Bezafibrate may be an effective alternative for managing severe hyperlipidemia in patients with specific LPL gene mutations who are resistant to fenofibrate and atorvastatin.
Answers are grounded in this paper and cite their sources.
May prompt LPL screening in refractory hyperlipidemia with MIDD; leaves open optimal management strategies.
Maternally inherited diabetes and deafness is a rare genetic disease mainly caused by a point mutation in mitochondrial deoxyribonucleic acid. Lipoprotein lipase gene mutations are associated with familial dyslipidemias, which are difficult to manage. We reported for the first time a case that had both maternally inherited diabetes and severe hyperlipidemia caused by lipoprotein lipase gene mutation (C.347(exon3)G>C) that was resistant to fenofibrate and atorvastatin. We were able to manage the patient's hyperlipidemia with bezafibrate, and her diabetes was well controlled with insulin. In conclusion, genetic testing is helpful in identifying rare and interesting cases when clinicians suspect inheritable diseases. Additionally, when one fibrate drug is ineffective in treating hyperlipidemia, it might be worthwhile trying another fibrate.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: